专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US06329525B1 1,2-Dihydro-2-oxoquinoline derivatives 失效
标题翻译： 1,2-二氢-2-氧代喹啉衍生物
公开(公告)号：US06329525B1
公开(公告)日：2001-12-11
申请号：US09555568
申请日：2000-06-01
申请人： Atsuro Nakazato , Taketoshi Okubo , Toshihito Kumagai , Shigeyuki Chaki , Kazuyuki Tomisawa , Masashi Nagamine , Makoto Gotoh , Masanori Yoshida
发明人： Atsuro Nakazato , Taketoshi Okubo , Toshihito Kumagai , Shigeyuki Chaki , Kazuyuki Tomisawa , Masashi Nagamine , Makoto Gotoh , Masanori Yoshida
IPC分类号： C07D215227
CPC分类号： C07D401/06 , C07D215/54 , C07D241/44
摘要： A 1,2-dihydro-2-oxoquinoline derivative represented by the formula: wherein Ar is a pyridyl group or a group represented by the formula: (wherein X3 and X4 are the same or different, and are each a hydrogen atom, a halogen atom, a C1-5 alkyl group, a C1-5 alkoxy group, a hydroxyl group or a trifluoromethyl group), Y is a nitrogen atom, CH or C(OH), R1 and R2 are the same or different, and are each a hydrogen atom, a C1-10 alkyl group, a C3-15 alkoxyalkyl group or a C3-15 alkylaminoalkyl group, or R1 and R2 taken together with the nitrogen atom to which they are attached form a cyclic amino group, X1 and X2 are the same or different, and are each a hydrogen atom, a C1-5 alkyl group, a C1-5 alkoxy group or a halogen atom, or X1 and X2 taken together form an alkylenedioxy group, and n is an integer of 1 to 3; or a pharmaceutically acceptable salt thereof.
摘要翻译：由下式表示的1,2-二氢-2-氧代喹啉衍生物：其中Ar是吡啶基或由下式表示的基团：（其中X 3和X 4相同或不同，并且各自为氢原子，卤素原子，C 1-5烷基，C 1-5烷氧基，羟基或三氟甲基），Y是氮原子，CH或C（OH），R 1和R 2相同或不同，各自相同或不同氢原子，C 1-10烷基，C 3-15烷氧基烷基或C 3-15烷基氨基烷基，或者R 1和R 2与它们所连接的氮原子一起形成环状氨基，X 1和X 2是相同或不同，各自为氢原子，C1-5烷基，C1-5烷氧基或卤素原子，或X1和X2一起形成亚烷基二氧基，n为1〜3的整数 ; 或其药学上可接受的盐。

2. 发明授权

US06281355B1 Nitrogen-containing tetracyclic compounds 失效
标题翻译：含氮四环化合物
公开(公告)号：US06281355B1
公开(公告)日：2001-08-28
申请号：US09555570
申请日：2000-06-01
申请人： Atsuro Nakazato , Taketoshi Okubo , Toshihito Kumagai , Shigeyuki Chaki , Kazuyuki Tomisawa , Masashi Nagamine , Makoto Gotoh , Kuniaki Kondoh , Masanori Yoshida
发明人： Atsuro Nakazato , Taketoshi Okubo , Toshihito Kumagai , Shigeyuki Chaki , Kazuyuki Tomisawa , Masashi Nagamine , Makoto Gotoh , Kuniaki Kondoh , Masanori Yoshida
IPC分类号： A61K31403
CPC分类号： C07D471/04 , C07D495/04
摘要： A nitrogen-containing tetracyclic compound represented by the formula: wherein Y1—Y2—Y3 is N—C═N or a group represented by the formula: C═C—NR3 (wherein R3 is a hydrogen atom, a C1-5 alkyl group or a nitrogen-containing C2-10 alkyl group), Y4 is S, SO, SO2, CH2 or a group represented by the formula: NR4 (wherein R4 is a C1-5 alkanoyl group or a C1-5 alkyl group), R1 and R2 are the same or different, and are each a hydrogen atom, a C1-10 alkyl group, a C3-15 alkoxyalkyl group or a C3-15 alkylaminoalkyl group, or R1 and R2 taken together with the nitrogen atom to which they are attached form a cyclic amino group, X1 and X2 are the same or different, and are each a hydrogen atom, a C1-5 alkyl group, a C1-5 alkoxy group or a halogen atom, and n is 0, 1 or 2; or a pharmaceutically acceptable salt thereof.
摘要翻译：一种由下式表示的含氮四环化合物：其中Y1-Y2-Y3为NC = N或由下式表示的基团：C = C-NR3（其中R3为氢原子，C1-5烷基或含氮的C2-10烷基），Y4是S，SO，SO2，CH2或由下式表示的基团：NR4（其中R4是C1-5烷酰基或C1-5烷基），R1和R2 各自为氢原子，C 1-10烷基，C 3-15烷氧基烷基或C 3-15烷基氨基烷基，或者R 1和R 2与它们所连接的氮原子一起形成环状氨基，X1和X2相同或不同，分别为氢原子，C1-5烷基，C1-5烷氧基或卤素原子，n为0,1或2; 或其药学上可接受的盐。

3. 发明授权

US06380384B1 1,2-dihydro-2-oxoquinoline derivatives 失效
标题翻译： 1,2-二氢-2-氧代喹啉衍生物
公开(公告)号：US06380384B1
公开(公告)日：2002-04-30
申请号：US09829203
申请日：2001-04-10
申请人： Atsuro Nakazato , Taketoshi Okubo , Toshihito Kumagai , Shigeyuki Chaki , Kazuyuki Tomisawa , Masashi Nagamine , Makoto Gotoh , Masanori Yoshida
发明人： Atsuro Nakazato , Taketoshi Okubo , Toshihito Kumagai , Shigeyuki Chaki , Kazuyuki Tomisawa , Masashi Nagamine , Makoto Gotoh , Masanori Yoshida
IPC分类号： C07D40106
CPC分类号： C07D401/06 , C07D215/54 , C07D241/44
摘要： A 1,2-dihydro-2-oxoquinoline derivative represented by the formula: wherein Ar is a pyridyl group or a group represented by the formula: (wherein X3 and X4 are the same or different, and are each a hydrogen atom, a halogen atom, a C1-5 alkyl group, a C1-5 alkoxy group, a hydroxyl group or a trifluoromethyl group), Y is a nitrogen atom, CH or C(OH), R1 and R2 are the same or different, and are each a hydrogen atom, a C1-10 alkyl group, a C3-15 alkoxyalkyl group or a C3-15 alkylaminoalkyl group, or R1 and R2 taken together with the nitrogen atom to which they are attached form a cyclic amino group, X1 and X2 are the same or different, and are each a hydrogen atom, a C1-5 alkyl group, a C1-5 alkoxy group or a halogen atom; or X1 and X2 taken together form an alkylenedioxy group, and n is an integer of 1 to 3; or a pharmaceutically acceptable salt thereof.
摘要翻译：由下式表示的1,2-二氢-2-氧代喹啉衍生物：其中Ar是吡啶基或由下式表示的基团：（其中X 3和X 4相同或不同，并且各自为氢原子，卤素原子，C 1-5烷基，C 1-5烷氧基，羟基或三氟甲基），Y是氮原子，CH或C（OH），R 1和R 2相同或不同，各自相同或不同氢原子，C 1-10烷基，C 3-15烷氧基烷基或C 3-15烷基氨基烷基，或者R 1和R 2与它们所连接的氮原子一起形成环状氨基，X 1和X 2是相同或不同，并且各自为氢原子，C1-5烷基，C1-5烷氧基或卤素原子; 或者X1和X2一起形成亚烷基二氧基，n为1〜3的整数。或其药学上可接受的盐。

4. 发明授权

US06476056B2 Heterocycle substituted aryloxyaniline derivatives and their use as MDR ligands 失效
标题翻译：杂环取代的芳氧基苯胺衍生物及其作为MDR配体的用途
公开(公告)号：US06476056B2
公开(公告)日：2002-11-05
申请号：US09922807
申请日：2001-08-07
申请人： Atsuro Nakazato , Taketoshi Okubo , Toshio Nakamura , Shigeyuki Chaki , Kazuyuki Tomisawa , Masashi Nagamine , Kenji Yamamoto , Koichiro Harada , Masanori Yoshida
发明人： Atsuro Nakazato , Taketoshi Okubo , Toshio Nakamura , Shigeyuki Chaki , Kazuyuki Tomisawa , Masashi Nagamine , Kenji Yamamoto , Koichiro Harada , Masanori Yoshida
IPC分类号： A61K3144
CPC分类号： C07D213/40 , C07C233/25 , C07C233/33 , C07C233/54 , C07C235/38 , C07C235/78 , C07C237/30 , C07C247/10 , C07C275/32 , C07C311/27 , C07C311/29 , C07C311/46 , C07C323/20 , C07C323/41 , C07C323/60 , C07D213/643 , C07D213/65 , C07D213/68
摘要： An aryloxyaniline derivative represented by the formula: wherein Ar1 and Ar2 are the same or different, and are each a substituted or unsubstituted phenyl group, a substituted or unsubstituted pyridyl group or a naphthyl group, provided that Ar1 and Ar2 are not both phenyl or both naphthyl and are not phenyl and naphthyl, R1 is a hydrogen atom, a substituted or unsubstituted alkyl group having 1 to 10 carbon atoms, an alkoxy group having 1 to 10 carbon atoms, a substituted or unsubstituted phenyl group or a group of the formula: —NR2(R3) (wherein R2 and R3 are the same or different, and are each a hydrogen atom or an alkyl group having 1 to 10 carbon atoms, X1 is a hydrogen atom, an alkyl group having 1 to 5 carbon atoms, an alkoxy group having 1 to 5 carbon atoms, a phenoxy group, a halogen atom, a trifluoromethyl group, a carbamoyl group or an aminosulfonyl group, Y1 is a branched or unbranched alkylene group having 1 to 6 carbon atoms or a single bond; and pharmaceutically acceptable salts thereof.
摘要翻译：由下式表示的芳氧基苯胺衍生物：其中Ar1和Ar2相同或不同，并且各自为取代或未取代的苯基，取代或未取代的吡啶基或萘基，条件是Ar 1和Ar 2不同时为苯基或两者萘基，不是苯基和萘基，R1是氢原子，取代或未取代的碳原子数1〜10的烷基，碳原子数1〜10的烷氧基，取代或未取代的苯基或下式的基团： -NR2（R3）（其中R2和R3相同或不同，并且各自为氢原子或具有1-10个碳原子的烷基，X 1为氢原子，具有1至5个碳原子的烷基，具有1至5个碳原子的烷氧基，苯氧基，卤素原子，三氟甲基，氨基甲酰基或氨基磺酰基，Y1是具有1至6个碳原子或单键的支链或非支链亚烷基; 可以接受的盐。

5. 发明授权

US06333358B1 Aryloxyaniline derivatives 失效
标题翻译：芳氧基苯胺衍生物
公开(公告)号：US06333358B1
公开(公告)日：2001-12-25
申请号：US09485006
申请日：2000-02-01
申请人： Atsuro Nakazato , Taketoshi Okubo , Toshio Nakamura , Shigeyuki Chaki , Kazuyuki Tomisawa , Masashi Nagamine , Kenji Yamamoto , Koichiro Harada , Masanori Yoshida
发明人： Atsuro Nakazato , Taketoshi Okubo , Toshio Nakamura , Shigeyuki Chaki , Kazuyuki Tomisawa , Masashi Nagamine , Kenji Yamamoto , Koichiro Harada , Masanori Yoshida
IPC分类号： A61K31135
CPC分类号： C07D213/40 , C07C233/25 , C07C233/33 , C07C233/54 , C07C235/38 , C07C235/78 , C07C237/30 , C07C247/10 , C07C275/32 , C07C311/27 , C07C311/29 , C07C311/46 , C07C323/20 , C07C323/41 , C07C323/60 , C07D213/643 , C07D213/65 , C07D213/68
摘要： An aryloxyaniline derivative represented by the formula: wherein Ar1 and Ar2 are each a substituted or unsubstituted phenyl group, pyridyl group or naphthyl group, R1 is a hydrogen atom, an alkyl group, etc., X1 is a hydrogen atom, an alkyl group, etc., y1 is a branched or unbranched alkylene group having 1 to 6 carbon atoms or a single bond; or a pharmaceutically acceptable salt thereof can provide medicines having a high affinity for MDR, and therefore, exhibiting a therapeutic or preventive effect on anxiety, related diseases thereto, depression, etc.
摘要翻译：由下式表示的芳氧基苯胺衍生物：其中Ar1和Ar2各自为取代或未取代的苯基，吡啶基或萘基，R1为氢原子，烷基等，X1为氢原子，烷基， y1是具有1〜6个碳原子或单键的支链或非支链亚烷基; 或其药学上可接受的盐可以提供对MDR具有高亲和力的药物，因此对焦虑，其相关疾病，抑郁等具有治疗或预防作用。

6. 发明授权

US06187781B1 4-Tetrahydropyridylpyrimidine derivatives 失效
标题翻译： 4-四氢吡啶基嘧啶衍生物
公开(公告)号：US06187781B1
公开(公告)日：2001-02-13
申请号：US09381462
申请日：1999-09-21
申请人： Atsuro Nakazato , Toshihito Kumagai , Taketoshi Okubo , Izumi Aibe , Hideo Tanaka , Shigeyuki Chaki , Shigeru Okuyama , Kazuyuki Tomisawa
发明人： Atsuro Nakazato , Toshihito Kumagai , Taketoshi Okubo , Izumi Aibe , Hideo Tanaka , Shigeyuki Chaki , Shigeru Okuyama , Kazuyuki Tomisawa
IPC分类号： C07D40144
CPC分类号： C07D401/04 , C07D405/14 , C07D409/14
摘要： A 4-tetrahydropyridylpyrimidine compound represented by formula (I): wherein Ar represents a phenyl group substituted with 1 to 3 substituents selected from a halogen atom, an alkyl group having 1 to 5 carbon atoms, an alkoxy group having 1 to 5 carbon atoms, and a trifluoromethyl group, a phenyl group, a thienyl group or a furanyl group; R1 represents a hydrogen atom, an alkyl group having 1 to 5 carbon atoms, an amino group or an amino group substituted with 1 or 2 alkyl groups having 1 to 5 carbon atoms; R2 represents an alkyl group having 1 to 5 carbon atoms, a cycloalkylalkyl group having 4 to 7 carbon atoms, an alkenyl group having 2 to 5 carbon atoms or an alkynyl group having 2 to 5 carbon atoms; and X1, X2, and X3, which may be the same or different, each represent a hydrogen atom, a halogen atom, an alkyl group having 1 to 5 carbon atoms, an alkoxy group having 1 to 5 carbon atoms, an alkylthio group having 1 to 5 carbon atoms, an amino group or an amino group substituted with 1 or 2 alkyl groups having 1 to 5 carbon atoms, or a pharmaceutically acceptable salt thereof. The 4-Tetrahydropyridylpyrimidine compound finds utility in the treatment of diseases in which CRF is implicated.
摘要翻译：由式（I）表示的4-四氢吡啶基嘧啶化合物：其中Ar表示被1至3个选自卤素原子，具有1至5个碳原子的烷基，具有1至5个碳原子的烷氧基的取代基取代的苯基，和三氟甲基，苯基，噻吩基或呋喃基; R1表示氢原子，碳原子数1〜5的烷基，氨基或被1〜2个碳原子数1〜2的烷基取代的氨基。 R2表示碳原子数1〜5的烷基，碳原子数4〜7的环烷基烷基，碳原子数2〜5的烯基或碳原子数2〜5的炔基。 X 1，X 2和X 3可以相同或不同，分别表示氢原子，卤素原子，碳原子数1〜5的烷基，碳原子数1〜5的烷氧基，烷硫基， 1至5个碳原子的氨基或被1或2个具有1至5个碳原子的烷基取代的氨基，或其药学上可接受的盐。 4-四氢吡啶基嘧啶化合物可用于治疗涉及CRF的疾病。

7. 发明授权

US06894168B2 Carbamoyl tetrahydropyridine derivatives 失效
标题翻译：氨基甲酰四氢吡啶衍生物
公开(公告)号：US06894168B2
公开(公告)日：2005-05-17
申请号：US10347288
申请日：2003-01-21
申请人： Atsuro Nakazato , Taketoshi Okubo , Toshihito Kumagai , Kazuyuki Tomisawa
发明人： Atsuro Nakazato , Taketoshi Okubo , Toshihito Kumagai , Kazuyuki Tomisawa
IPC分类号： A61K31/519 , A61P1/00 , A61P7/10 , A61P9/10 , A61P9/12 , A61P17/02 , A61P25/08 , A61P25/16 , A61P25/22 , A61P25/24 , A61P25/28 , A61P25/30 , A61P29/00 , A61P37/02 , A61P43/00 , C07D473/00 , C07D487/04 , C07D211/78
CPC分类号： A61K31/519 , C07D473/00 , C07D487/04
摘要： Carbamoyl tetrahydropyridine derivatives represented by the formula: [in the formula, R1 and R2 are identical or different, and each represents a hydrogen atom, a C1-C5 alkyl group, or the like; Y1—Y2 represents (R4)C═C(R5), (R6)C═N, N═N, (R7) N—CO, or N═C(R8); X1, X2, and X3 are identical or different, and each represents a hydrogen atom, a halogen atom, or the like; R3, R4, R5, and R6 are identical or different, and each represents a hydrogen atom or an alkyl group; R7 represents a hydrogen atom, a C1-C5 alkyl group, or the like; and R8 represents a hydrogen atom or a carbamoyl group] or a pharmaceutically acceptable salt thereof, and intermediates for the preparation thereof are provided. The derivatives described above are effective for diseases which are believed to involve CRF.
摘要翻译：由下式表示的氨基甲酰基四氢吡啶衍生物：[式中，R 1，R 2和R 2'相同或不同，各自表示氢原子，C 1 C 5 -C 15烷基等; Y 1 - （CH 2）2（R 4 S）（R 5），（R 6） CN，NN，（R 7）N-CO或NC（R 8）; X 1，X 2和X 3相同或不同，各自表示氢原子，卤素原子等; R 3，R 4，R 5和R 6相同或不同，并且各自表示氢原子或烷基; R 7表示氢原子，C 1 -C 5烷基等; 和R 8表示氢原子或氨基甲酰基]或其药学上可接受的盐，以及其制备中间体。上述衍生物对于被认为涉及CRF的疾病是有效的。

8. 发明授权

US06600038B1 Carbamoyl tetrahydropyridine derivatives 失效
标题翻译：氨基甲酰四氢吡啶衍生物
公开(公告)号：US06600038B1
公开(公告)日：2003-07-29
申请号：US09914534
申请日：2001-08-30
申请人： Atsuro Nakazato , Taketoshi Okubo , Toshihito Kumagai , Kazuyuki Tomisawa
发明人： Atsuro Nakazato , Taketoshi Okubo , Toshihito Kumagai , Kazuyuki Tomisawa
IPC分类号： C07D47334
CPC分类号： A61K31/519 , C07D473/00 , C07D487/04
摘要： Carbamoyl tetrahydropyridine derivatives represented by the formula: [in the formula, R1 and R2 are identical or different, and each represents a hydrogen atom, a C1-C5 alkyl group, or the like; Y1-Y2 represents (R4)C═C(R5), (R6)C═N, N═N, (R7)N—CO, or N═C(R8); X1, X2, and X3 are identical or different, and each represents a hydrogen atom, a halogen atom, or the like; R3, R4, R5, and R6 are identical or different, and each represents a hydrogen atom or an alkyl group; R7 represents a hydrogen atom, a C1-C5 alkyl group, or the like; and R8 represents a hydrogen atom or a carbamoyl group] or a pharmaceutically acceptable salt thereof, and intermediates for the preparation thereof are provided. The derivatives described above are effective for diseases which are believed to involve CRF.
摘要翻译：由下式表示的氨基甲酰基四氢吡啶衍生物：[式中，R 1和R 2相同或不同，各自表示氢原子，C 1 -C 5烷基等; Y1-Y2表示（R4）C = C（R5），（R6）C = N，N = N，（R7）N-CO或N = C（R8） X1，X2和X3相同或不同，各自表示氢原子，卤素原子等; R3，R4，R5和R6相同或不同，各自表示氢原子或烷基; R7表示氢原子，C1-C5烷基等; 并且R8表示氢原子或氨基甲酰基]或其药学上可接受的盐，并且提供其制备的中间体。上述衍生物对于被认为涉及CRF的疾病是有效的。

9. 发明授权

US06949552B2 Remedial agent for anxiety neurosis or depression and piperazine derivative 失效
标题翻译：焦虑神经症或抑郁症和哌嗪衍生物的补救剂
公开(公告)号：US06949552B2
公开(公告)日：2005-09-27
申请号：US10311429
申请日：2001-06-27
申请人： Atsuro Nakazato , Shigeyuki Chaki , Taketoshi Okubo , Shin-ichi Ogawa , Takaaki Ishii
发明人： Atsuro Nakazato , Shigeyuki Chaki , Taketoshi Okubo , Shin-ichi Ogawa , Takaaki Ishii
IPC分类号： A61K31/495 , A61K31/496 , A61K45/06 , A61P25/22 , A61P25/24 , C07D295/125 , C07D401/06 , C07D403/06 , C07D413/14
CPC分类号： C07D295/125 , A61K31/495 , A61K31/496 , A61K45/06 , C07C2601/02 , C07C2601/08 , C07C2601/14
摘要： There are provided a therapeutic preparation for anxiety neurosis or depression which comprises a MC4 receptor antagonist as an effective ingredient; and a piperazine derivative represented by Formula [1]: [wherein Ar1 is a phenyl group, a substituted phenyl group, a naphthyl group or a substituted naphthyl group; Ar2 is a naphthyl group, a substituted naphthyl group, a quinolyl group, a group represented by the formula: (wherein R4 is a hydrogen atom or a halogen atom; and X—Y is CH—NH, CH—O, CH—S or N—O) or a group represented by the formula: (wherein R5 is a hydrogen atom, a hydroxyl group or a C1-10 alkoxy group); R1 is a hydrogen atom, a C1-10 alkyl group, a C3-8 cycloalkyl group, a C3-10 alkenyl group, a phenyl group, a 1-cyanoethyl group, a pyrimidin-2-yl group or an amidyl group; R2 and R3 are the same or different, and are each a hydrogen atom or a C1-10 alkyl group; A-B is N—CH2, CH—CH2, C(OH)—CH2 or C═CH; T1 is a single bond, —N(R6)— (wherein R6 is a hydrogen atom or a C1-10 alkyl group), —O—, —CH═CH— or —C(═O)—; n is an integer of from 1 to 10 and when T1 is a single bond, —CH═CH— or —C(═O)—, n is an integer of from 2 to 10 when T1 is —N(R6)— or —O—], or a pharmaceutically acceptable salt thereof.
摘要翻译：提供焦虑性神经症或抑郁症的治疗剂，其包含作为有效成分的MC 4受体拮抗剂; 和由式[1]表示的哌嗪衍生物：其中Ar 1是苯基，取代的苯基，萘基或取代的萘基; Ar 2是萘基，取代的萘基，喹啉基，由下式表示的基团：（其中R 4是氢原子或卤素原子; 并且XY是CH-NH，CH-O，CH-S或NO）或由下式表示的基团：（其中R 5是氢原子，羟基或C 1-10个烷氧基）; R 1是氢原子，C 1-10烷基，C 3-8环烷基，C 3 -10个链烯基，苯基，1-氰基乙基，嘧啶-2-基或酰氨基; R 2和R 3相同或不同，并且各自为氢原子或C 1-10烷基; A-B是N-CH 2，CH-CH 2，C（OH）-CH 2或C-CH; T 1是单键，-N（R 6） - （其中R 6是氢原子或C 1 -10个烷基），-O - ， - CH-CH-或-C（ - O） - ; n是1〜10的整数，当T 1是单键时，-CH-CH-或-C（-O） - ，n是2〜10的整数，当T 或其药学上可接受的盐，其中R 1是-N（R 6） - 或-O-]。

10. 发明授权

US06852732B2 Tetrahydropyridino or piperidino heterocylic derivatives 失效
标题翻译：四氢吡啶基或哌啶子杂环衍生物
公开(公告)号：US06852732B2
公开(公告)日：2005-02-08
申请号：US10311277
申请日：2001-07-04
申请人： Atsuro Nakazato , Toshihito Kumagai , Taketoshi Okubo , Kazuya Kameo
发明人： Atsuro Nakazato , Toshihito Kumagai , Taketoshi Okubo , Kazuya Kameo
IPC分类号： A61K31/4365 , A61K31/437 , A61K31/4375 , A61K31/4439 , A61K31/4709 , A61K31/502 , A61K31/506 , A61K31/517 , A61K31/519 , A61K31/53 , A61K31/5377 , A61P1/00 , A61P1/14 , A61P7/10 , A61P9/00 , A61P9/10 , A61P9/12 , A61P17/14 , A61P25/00 , A61P25/14 , A61P25/16 , A61P25/22 , A61P25/24 , A61P25/28 , A61P25/30 , A61P29/00 , A61P37/02 , A61P43/00 , C07D401/04 , C07D401/14 , C07D417/04 , C07D471/04 , C07D487/04 , C07D495/04 , C07D498/04 , C07D513/04 , A01N43/42
CPC分类号： C07D401/04 , C07D401/14 , C07D417/04 , C07D471/04 , C07D487/04 , C07D495/04 , C07D513/04
摘要： A tetrahydropyridino or piperidino heterocyclic derivative represented by the formula [I]: A-Het [I] has a high affinity for CRF receptors and is effective against diseases in which CRF is considered to be involved.
摘要翻译：由式[I]表示的四氢吡啶基或哌啶子基杂环衍生物对CRF受体具有高亲和力，并且对于被认为涉及CRF的疾病有效。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式